Market News & Trends
VIVEbiotech Continues Expansion of its Lentiviral Vector Manufacturing Capabilities to Address the Viral Vector Bottleneck
VIVEbiotech, S.L. recently announced its Good Manufacturing Practice (GMP)-accredited new facility is now fully operational after receiving the renewal of its GMP accreditation for a…
EyePoint Pharmaceuticals & OcuMension Therapeutics Announce Approval of NDA for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics recently announced China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved YUTIQ (fluocinolone…
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation recently announced the creation of a subgroup of researchers to focus on cancer treatment. ….
Acer Therapeutics & Relief Therapeutics Announce Update on US FDA Review of NDA
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics recently announced the US FDA has issued a Complete Response Letter (CRL) regarding the New Drug…
Valneva & Pfizer Enter Equity Subscription Agreement & Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. recently announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15…..
Hepion Pharmaceuticals Receives Orphan Drug Status Designation for the Treatment of Hepatocellular Carcinoma
Hepion Pharmaceuticals, Inc. recently announced the US FDA has granted Orphan Drug Designation to rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment…
Mitsubishi Gas Chemical & BD Have Signed LOI to Discuss Partnership Agreement to Explore New Ways to Advance Biologic Drug Delivery
Mitsubishi Gas Chemical Company, Inc. and BD recently announced they have entered into an agreement to investigate further development of OXYCAPT – an innovation from MGC that integrates….
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
VYNE Therapeutics Inc. recently announced the completion of enrollment in the Phase 2a study of FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD). FMX114…
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
Cyclerion Therapeutics, Inc. recently announced research from preclinical studies demonstrating treatment with its lead soluble guanylate cyclase (sGC) stimulator, CY6463, was associated with improved cellular…
INmune Bio, Inc. Presents Data on Combination Therapy With INB03 on Overcoming Resistance to HER2-Targeted Therapies in Breast Cancer
INmune Bio, Inc. has been invited to present data on reversing resistance to HER2-targeted immunotherapy at the HER2-Targeted Therapy Summit in Boston. Mucin 4 (MUC4),…
Owen Mumford Appoints New Director of R&D
Owen Mumford, a global leader in the design, manufacture, and advancement of medical devices recently announced it has appointed….
MD Anderson, Invectys and CTMC Announce Strategic Collaboration for CAR T Cell Therapy Development
The University of Texas MD Anderson Cancer Center, Invectys, Inc., and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National…
Aptamer Group Signs Deal With Flip Gene Therapeutics to Support the Development of Inducible Gene Therapies
Aptamer Group plc has recently negotiated a deal with the biotechnology company Flip Gene Therapeutics to support its novel, inducible gene therapy platform with the…
Kintara Therapeutics Granted Fast Track Designation for VAL-083 for Newly Diagnosed Glioblastoma
Kintara Therapeutics, Inc. recently announced the US FDA has granted Fast Track Designation (FTD) to Kintara’s VAL-083 for the treatment of patients with newly diagnosed…
Kindeva Drug Delivery Announces Collaboration With Synopsys
Kindeva Drug Delivery recently announced a collaboration with Synopsys, Inc. involving the implementation of Synopsys Simpleware automated software solutions to assist in creating….
medmix Drug Delivery (Haselmeier) Launches its First Fully Featured Autoinjector
medmix Drug Delivery introduces PiccoJect, a disposable two-step autoinjector designed for subcutaneous injection. The device is being developed in two variants (PiccoJect 100 and PiccoJect 225) for a standard….
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD With AIM Biologicals Program
Aeterna Zentaris Inc. recently announced its Autoimmunity Modifying (AIM) Biologicals program has achieved preclinical proof-of-concept for the potential treatment of neuromyelitis optica spectrum disorder (NMOSD)…
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, a Type of Brain Cancer That Affects Predominantly Pediatric Patients
Nuvectis Pharma, Inc. recently announced positive data for NXP900 in a preclinical xenograft model of Group 4 Medulloblastoma presented on June 12, 2022, at SIOPE Brain Tumour Group in Hamburg, Germany, by scientists….
Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia
Veralox Therapeutics recently announced favorable results from the company's Phase 1 clinical program for VLX-1005, a novel 12-LOX inhibitor being developed for the treatment and…
MERXIN & Gerresheimer Worked Successfully Together to Realize the Shortest Possible Time to Market for the MERXIN MRX003 Capsule DPI
Gerresheimer has assumed responsibility for the industrialization of a dry powder inhaler for the treatment of respiratory ailments for MERXIN (United Kingdom), a company that…
